Found: 114
Select item for more details and to access through your institution.
Prevalence of alternative lengthening of telomeres in pediatric sarcomas determined by the telomeric DNA C-circle assay.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1399442
- By:
- Publication type:
- Article
Non‐synonymous, synonymous, and non‐coding nucleotide variants contribute to recurrently altered biological processes during retinoblastoma progression.
- Published in:
- Genes, Chromosomes & Cancer, 2023, v. 62, n. 5, p. 275, doi. 10.1002/gcc.23120
- By:
- Publication type:
- Article
Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.
- Published in:
- British Journal of Pharmacology, 2014, v. 171, n. 23, p. 5330, doi. 10.1111/bph.12846
- By:
- Publication type:
- Article
Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure.
- Published in:
- 2011
- By:
- Publication type:
- journal article
MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.
- Published in:
- Cell Death & Disease, 2020, v. 11, n. 5, p. 1, doi. 10.1038/s41419-020-2563-4
- By:
- Publication type:
- Article
Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
- Published in:
- Experimental Biology & Medicine, 2017, v. 242, n. 11, p. 1178, doi. 10.1177/1535370217706952
- By:
- Publication type:
- Article
Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.
- Published in:
- Experimental Biology & Medicine, 2014, v. 239, n. 10, p. 1390, doi. 10.1177/1535370214538745
- By:
- Publication type:
- Article
ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156.
- Published in:
- Science Translational Medicine, 2021, v. 13, n. 607, p. 1, doi. 10.1126/scitranslmed.abd5750
- By:
- Publication type:
- Article
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
- Published in:
- Science Translational Medicine, 2018, v. 10, n. 441, p. 1, doi. 10.1126/scitranslmed.aao4680
- By:
- Publication type:
- Article
Mechanism of Synergy of N-(4-Hydroxyphenyl) Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: McI-1 Inactivation.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 8, p. 580, doi. 10.1093/jnci/djn076
- By:
- Publication type:
- Article
Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2007, v. 99, n. 14, p. 1107, doi. 10.1093/jnci/djm044
- By:
- Publication type:
- Article
Ras and Seppuku in neuroblastoma.
- Published in:
- 2002
- By:
- Publication type:
- commentary
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01641
- By:
- Publication type:
- Article
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01355
- By:
- Publication type:
- Article
Alpha-smooth-muscle actin and desmin expressions in human neuroblastoma cell lines.
- Published in:
- International Journal of Cancer, 1991, v. 48, n. 2, p. 277, doi. 10.1002/ijc.2910480221
- By:
- Publication type:
- Article
Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor.
- Published in:
- EMBO Molecular Medicine, 2021, v. 13, n. 2, p. 1, doi. 10.15252/emmm.202012640
- By:
- Publication type:
- Article
The diagnostic dilemma of the "small round cell neoplasm": catecholamine fluorescence and tissue culture morphology as markers for neuroblastoma.
- Published in:
- 1981
- By:
- Publication type:
- journal article
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
- Published in:
- Nature Genetics, 2013, v. 45, n. 1, p. 12, doi. 10.1038/ng.2493
- By:
- Publication type:
- Article
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma.
- Published in:
- Nature, 1985, v. 313, n. 6001, p. 404, doi. 10.1038/313404a0
- By:
- Publication type:
- Article
miR‐15a‐5p, miR‐15b‐5p, and miR‐16‐5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
- Published in:
- Molecular Oncology, 2020, v. 14, n. 1, p. 180, doi. 10.1002/1878-0261.12588
- By:
- Publication type:
- Article
Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines.
- Published in:
- PLoS ONE, 2013, v. 8, n. 12, p. 1, doi. 10.1371/journal.pone.0080060
- By:
- Publication type:
- Article
Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts.
- Published in:
- PLoS ONE, 2012, v. 7, n. 3, p. 1, doi. 10.1371/journal.pone.0033894
- By:
- Publication type:
- Article
Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Pilot study of intravenous melphalan combined with continuous infusion L- S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
- Published in:
- Pediatric Blood & Cancer, 2015, v. 62, n. 10, p. 1739, doi. 10.1002/pbc.25594
- By:
- Publication type:
- Article
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2015, v. 62, n. 6, p. 1106, doi. 10.1002/pbc.25329
- By:
- Publication type:
- Article
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
- Published in:
- Pediatric Blood & Cancer, 2015, v. 62, n. 1, p. 91, doi. 10.1002/pbc.25201
- By:
- Publication type:
- Article
Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 11, p. 1972, doi. 10.1002/pbc.25175
- By:
- Publication type:
- Article
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 8, p. 1493, doi. 10.1002/pbc.25026
- By:
- Publication type:
- Article
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 8, p. 1486, doi. 10.1002/pbc.24989
- By:
- Publication type:
- Article
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 5, p. 922, doi. 10.1002/pbc.24800
- By:
- Publication type:
- Article
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 2, p. 245, doi. 10.1002/pbc.24724
- By:
- Publication type:
- Article
Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 1, p. 158, doi. 10.1002/pbc.24616
- By:
- Publication type:
- Article
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 11, p. 1801, doi. 10.1002/pbc.24643
- By:
- Publication type:
- Article
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 11, p. 1860, doi. 10.1002/pbc.24647
- By:
- Publication type:
- Article
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 8, p. 1325, doi. 10.1002/pbc.24517
- By:
- Publication type:
- Article
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 7, p. E42, doi. 10.1002/pbc.24451
- By:
- Publication type:
- Article
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 5, p. 783, doi. 10.1002/pbc.24368
- By:
- Publication type:
- Article
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 5, p. 791, doi. 10.1002/pbc.24301
- By:
- Publication type:
- Article
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 4, p. 633, doi. 10.1002/pbc.24235
- By:
- Publication type:
- Article
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 7, p. 1266, doi. 10.1002/pbc.24073
- By:
- Publication type:
- Article